FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3- fluoroazetidine-1-sulfonamide of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition based on it, as well as a method of treating a BRAF-associated tumour using them.
EFFECT: obtaining of 4-oxo-3,4-dihydroquinazolinone compounds for the treatment of BRAF-associated diseases and disorders.
25 cl, 1 dwg, 140 ex
| Title | Year | Author | Number |
|---|---|---|---|
| QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
| PROPOSED 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | 2022 |
|
RU2826000C1 |
| NEW BRAF INHIBITORS AS "PARADOX BREAKERS" | 2020 |
|
RU2825870C1 |
| PHARMACEUTICAL COMPOUNDS | 2019 |
|
RU2821941C2 |
| BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | 2020 |
|
RU2811612C2 |
| CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | 2018 |
|
RU2801302C2 |
| SPIROCYCLIC COMPOUNDS | 2016 |
|
RU2745069C2 |
| PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS TAM AND MET KINASE INHIBITORS | 2019 |
|
RU2773611C1 |
| NEW METHYLQUINAZOLINONE DERIVATIVES | 2020 |
|
RU2802968C1 |
| COMPOUND AS WNT SIGNAL INHIBITOR, ITS COMPOSITIONS AND APPLICATION | 2012 |
|
RU2627712C2 |
